ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2025
Detection of non-travel-associated, ceftriaxone non-susceptible
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This case report describes a young male with multidrug-resistant Methods: Case follow-up was conducted following routine public health practice in Ontario. Antimicrobial susceptibility testing of the isolate was done by agar dilution. Strain typing and other molecular characterization was done by whole genome sequencing. Results: The patient was treated successfully with intramuscular ceftriaxone and oral azithromycin. Agar dilution testing demonstrated reduced susceptibility to all tested agents, except for azithromycin and spectinomycin, including non-susceptibility to ceftriaxone (minimum inhibitory concentration [MIC]=0.5 mg/L) and cefixime (MIC=2 mg/L), resistance to tetracycline (MIC=2 mg/mL) and ciprofloxacin (MIC=32 mg/L), and testing intermediate to penicillin (MIC=1 mg/L). Whole-genome sequencing revealed the isolate was closely related to the FC428 clone, which harbours the mosaic Conclusion: Identification of this case suggests previously unrecognized local transmission of this multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.